Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are overtly healthy males or females, as determined through medical history and physical examination.~* Possess a valid driver's license and is an active driver at screening. Driven a minimum of 8,000 miles (about 13,000 kilometers) per year for the preceding 3 years.~* Have a score of \<10 on the Epworth Sleepiness Scale.~Exclusion Criteria:~* Have a history within 3 months of admission, or current treatment for, a sleeping disorder (including excessive snoring, obstructive sleep apnea), or a chronic painful condition that interferes with the subject's sleep.~* Have a history of difficulty either falling asleep or staying asleep in the previous 3 months of admission that is considered clinically significant by the investigator.~* Are expected to use any other medication or dietary supplement to promote sleep including over the-counter sleep medications, during their participation in the study.~* Have traveled across 2 or more time zones (transmeridian travel) in the past 2 weeks prior to randomization.~* Have worked in a night shift in the past 2 weeks prior to randomization.~* Show a history of central nervous system (CNS) conditions such as strokes, transient ischemic attacks, significant head trauma, seizures, CNS infections, migraine, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increase the risk of participating in the study.~* Show evidence of significant active neuropsychiatric disease (e.g., manic depressive illness, schizophrenia, depression) considered as clinically significant by the investigator.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally in one of four study periods.
- 100 milligrams (mg) Lasmiditan (Type: EXPERIMENTAL): 100 mg lasmiditan administered orally in one of four study periods.
- 200 mg Lasmiditan (Type: EXPERIMENTAL): 200 mg lasmiditan administered orally in one of four study periods.
- Diphenhydramine (Type: ACTIVE_COMPARATOR): 50 mg diphenhydramine administered orally in one of four study periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).